(19)
(11) EP 3 219 323 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.04.2021 Bulletin 2021/17

(45) Mention of the grant of the patent:
17.03.2021 Bulletin 2021/11

(21) Application number: 15859816.9

(22) Date of filing: 11.11.2015
(51) International Patent Classification (IPC): 
A61K 35/76(2015.01)
A61K 39/29(2006.01)
A61P 31/14(2006.01)
C12N 15/09(2006.01)
C12N 15/863(2006.01)
A61K 48/00(2006.01)
 A61K 31/7088(2006.01)
A61P 1/16(2006.01)
C12N 7/01(2006.01)
G01N 33/576(2006.01)
C07H 21/00(2006.01)
(86) International application number:
PCT/JP2015/082327
(87) International publication number:
WO 2016/076441 (19.05.2016 Gazette 2016/20)

(54)

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF HEPATITIS C

PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG UND/ODER PRÄVENTION VON HEPATITIS C

COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE L'HÉPATITE C

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 11.11.2014 JP 2014229283

(43) Date of publication of application:
20.09.2017 Bulletin 2017/38

(73) Proprietor: Nobelpharma Co., Ltd.
Chuo-ku Tokyo 104-0033 (JP)

(72) Inventors:
  • KOHARA, Michinori
    Tokyo 156-8506 (JP)
  • YASUTOMI, Yasuhiro
    Tsukuba-shi Ibaraki 305-0843 (JP)
  • SHIOGAMA, Yumiko
    Tsukuba-shi Ibaraki 305-0843 (JP)

(74) Representative: J A Kemp LLP 
14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
WO-A1-2014/176530
 US-A1- 2011 275 139
   
  • PANCHOLI P ET AL: "DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 77, no. 1, 1 January 2003 (2003-01-01), pages 382-390, XP002308334, ISSN: 0022-538X, DOI: 10.1128/JVI.77.1.382-390.2003
  • ANNE FOURNILLIER ET AL.: 'A Heterologous Prime/Boost VaccinationStrategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus' THE JOURNAL OF INFECTIOUS DISEASES vol. 208, no. 6, 15 September 2013, pages 1008 - 1019, XP055441226 DOI: 10.1093/INFDIS/JIT267
  • TAKESHI WADA ET AL.: 'DNA vaccine expressing the non-structural proteins of hepatitis C virus diminishes the expression of HCV proteins in a mouse model' VACCINE vol. 31, no. 50, 2013, pages 5968 - 5974, XP028776483 DOI: 10.1016/J.VACCINE.2013.10.037
  • YAO DENG ET AL.: 'Induction of Broadly Neutralising HCV Antibodies in Mice by Integration-Deficient Lentiviral Vector-Based Pseudotyped Particles' PLOS ONE vol. 8, no. 4, 2013, pages 1 1 - 7, XP055381180 DOI: 10.1371/JOURNAL.PONE.0062684
  • YUKIO KOIDE ET AL.: 'DNA Vaccine ni yoru Kansen Bogyo' BLOOD IMMUNITY CANCER vol. 7, no. 4, 2002, pages 372 - 384, XP009502891
  • YUMIKO SHIOGAMA ET AL.: 'C-gata Kan'en Virus ni Taisuru DNA Vaccine to Kumikae Vaccinia Virus o Mochiita Prime/Boost-ho ni yoru Kan'en Virus Tokuiteki Men'eki Fukatsuka Koka no Kento' THE 18TH ANNUAL MEETING OF THE JAPANESE SOCIETY FOR VACCINOLOGY PROGRAM SHOROKUSHU vol. 18 TH, 06 December 2014, page 127, XP009502935
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).